IMMUNOVANT INC. - CO

Immunovant Provides Update on Graves’ Disease Development Program

09 сен 2024 03:55:00 Источник Nasdaq GlobeNewswire

Immunovant to Host Graves’ Disease Program Update on September 9, 2024

05 сен 2024 06:30:00 Источник Nasdaq GlobeNewswire

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024

06 авг 2024 16:05:01 Источник Nasdaq GlobeNewswire

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

29 май 2024 16:01:00 Источник Nasdaq GlobeNewswire

Immunovant Awarded U.S. Patent for IMVT-1402

12 мар 2024 07:30:04 Источник Nasdaq GlobeNewswire

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023

12 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 янв 2024 08:00:00 Источник Nasdaq GlobeNewswire

Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease

20 дек 2023 16:30:00 Источник Nasdaq GlobeNewswire

Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

28 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Immunovant to Present at Upcoming Investor Conferences

13 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023

09 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional Shares

02 окт 2023 16:52:02 Источник Nasdaq GlobeNewswire

Immunovant Announces Pricing of $450 Million Common Stock Financing

27 сен 2023 23:41:51 Источник Nasdaq GlobeNewswire

Immunovant Announces Proposed Offering of $300 Million of Common Stock

26 сен 2023 17:00:00 Источник Nasdaq GlobeNewswire

Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

26 сен 2023 06:00:00 Источник Nasdaq GlobeNewswire

Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023

25 сен 2023 23:01:32 Источник Nasdaq GlobeNewswire

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023

10 авг 2023 07:00:01 Источник Nasdaq GlobeNewswire

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023

22 май 2023 07:00:00 Источник Nasdaq GlobeNewswire

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022

03 фев 2023 07:00:00 Источник Nasdaq GlobeNewswire

Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th

07 ноя 2022 08:00:01 Источник Nasdaq GlobeNewswire